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A novel approach in immunotherapy of human malig-
nancies is based on universal tumor associated antigen
(TAA)-specific T cell receptor (TCR) gene delivery into
human T cells. The MDM2 oncoprotein is overexpressed
in a multitude of human (Hu) malignancies, counter-bal-
ancing p53 as major tumor suppressor protein. We took
advantage of HuCD8xA2Kb transgenic (Tg) mice to bypass
human MDM2-specific self-tolerance: the chimeric MHC-
molecule of the xenogenic host enables the selection of
HLA-A2.1-restricted lymphocytes thereby allowing the
contribution of murine CD8 for TCR affinity maturation
in the thymus and the subsequent deployment of non-
tolerogenic lymphocytes into the periphery.
The TCR-encoding genes were retrovirally transduced in
human T cells in vitro. Quantitative expression frequency
of the heterodimeric TCR on a per cell basis was accom-
plished by introducing independent IRES selection cas-
settes into either TCRα/β construct so as to verify subtle
phenotype/structure/function characteristics among dif-
ferent TCR constructs.
A major concern was to determine as to whether or not
murine TCRs are able to form hybrid TCRs with the
endogenous ones potentially raising the issue of autoim-
munity. Based on empirical data one may hypothesize
that surface expression of a certain heterodimeric TCR
construct reflects it's intrinsic stability guided by it's pro-
pensity to heterodimerize and to be incorporated into the
multi-step assembly of the functional TCR/CD3 complex
so as to be sheltered from down-modulation and proteo-
lytic degradation. Amino acid substitutions that affect
interchain affinity will have an impact on surface expres-
sion, the formation of hybrid TCRs and functionality in
terms of cytokine secretion and cytolysis in chromium
release assays. For this a multitude of TCR constructs,
designed as either murine and partially humanized dou-
ble chain TCRs or as single chain TCRs, have been assayed
on their functional outcomes and consequences for the
endogenous TCRs. The expression of single murine TCR
chains documents their capability to form hybrid TCRs a
tendency that can be further increased by the humaniza-
tion of the constant domains. Point mutations that impair
pairing as deduced from protein structure reduce their sur-
face expression and inversly accumulate in the cyto-
plasma.
Murine double chain TCRs as opposed to humanized
TCRs are capable to compete with and to replace a signif-
icant fraction of the endogenous TCRs in an exogenous
TCR (exoTCR) dose dependent fashion irrespective of the
clonal TCR subfamily diversity of the particular donor.
Subsets of endogenous TCR high (endoTCRhi correlates
with exoTCRlo) and TCR low (endoTCRlo correlates with
exoTCRhi) expressing T cells have been FACS-sorted and
proceed to be verified for phenotype maintainance and
functional potency. One major intriguing topic is to pin-
point to the murine TCR structure determinants that are
responsible for this competing stringency in order to
introduce them into tumor-specific human TCRs for their
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favourable interchain pairing and subsequently their
exclusively heterologous expression in human T cells.Page 2 of 2
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